1267 results about "Cataracts" patented technology

A water jet instrument may be used for manually performing eye surgery such as, cataract, or perform micro-surgery (remove cartilage), or any emulsification technique. The water jet instrument may be manually controlled or controlled by a system with a robotic control. The water jet apparatus defines a jet cutting area that is based at least in part on a flow rate meter and a feedback loop.

Methods for the creation of microspheres treat the clear, intact crystalline lens of the eye with energy pulses, such as from lasers, for the purpose of correcting presbyopia, other refractive errors, and for the retardation and prevention of cataracts. Microsphere formation in non-contiguous patterns or in contiguous volumes works to change the flexure, mass, or shape of the crystalline lens in order to maintain or reestablish the focus of light passing through the ocular lens onto the macular area, and to maintain or reestablish fluid transport within the ocular lens.

A lithotripsy probe is used to break up cataracts, sinus blockages and other body masses, where the broken materials may be removed by suction. The lithotripsy probe may have a spark generator, a fluid motion generator, or other component for breaking up the body mass.

A light control and display technology applicable to light redirection and projection with the capacity, in a number of embodiments modified for particular applications, to produce managed light, including advanced images. Applications include miniature to very large scale video displays, optical data processing, 3-dimensional imaging, and lens-less vision enhancement for poor night-driving vision, cataracts and macular degeneration.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A lens is provided that having optical parameters that may be adjusted in-situ, and is particularly useful as an IOL for use in cataract patients that require an adjustment in the optical power of the lens post-implantation. In one embodiment, the lens body carries an array of interior fluid-filled cells in which fluid is controllably moved upon application of energy from an external source to move a fluid media into or out of the cells to thereby alter the lens surface shape.

An adaptive optic for refractive lens exchange or cataract patients. The intracapsular implant comprises an elastomeric monolith with an equilibrium memory shape that imparts to the capsular sac's periphery the natural shape of the capsule in an accommodated state. In one embodiment, the monolith carries a recessed deformable central lens portion having an ultralow modulus that allows for high accommodative amplitude in response to equatorial tensioning. In a preferred embodiment, the adaptive optic defines an anisotropic modulus with a plurality of on-axis, rotationally symmetric elastomer block portions each having a different Young's modulus. The invention further provides composite materials for enhancing deformation of lens curvature, including the use of auxetic polymeric materials and negative stiffness materials. In preferred embodiments, at least a portion of the lens is fabricated of a shape memory polymer that provides a memory shape and a temporary shape with a reduced cross-sectional shape for introduction into the patient's eye.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A water jet instrument may be used for manually performing eye surgery such as, cataract, or perform micro-surgery (remove cartilage), or any emulsification technique. The water jet instrument may be manually controlled or controlled by a system with a robotic control. The water jet apparatus defines a jet cutting area that is based at least in part on a flow rate meter and a feedback loop.

Systems and methods are described for cataract intervention. In one embodiment a system comprises a laser source configured to produce a treatment beam comprising a plurality of laser pulses; an integrated optical system comprising an imaging assembly operatively coupled to a treatment laser delivery assembly such that they share at least one common optical element, the integrated optical system being configured to acquire image information pertinent to one or more targeted tissue structures and direct the treatment beam in a 3-dimensional pattern to cause breakdown in at least one of the targeted tissue structures; and a controller operatively coupled to the laser source and integrated optical system, and configured to adjust the laser beam and treatment pattern based upon the image information, and distinguish two or more anatomical structures of the eye based at least in part upon a robust least squares fit analysis of the image information.

The invention concerns an improved tip (1) for oculistic surgery, particularly for the removal of cataract, having a proximal joint end (2) and a distal end (4), contacting the crystalline during the surgical intervention, wherein the distal end (4) contacting a corneal or sclera tissue is coated with an anti-friction treatment, based on carbon and tungsten carbide.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A deformable intracapsular implant device for shaping an enucleated lens capsule sac for use in cataract procedures and refractive lensectomy procedures. In one embodiment, the intraocular implant devices rely on thin film shape memory alloys and combine with the post-phaco capsular sac to provide a biomimetic complex that can mimic the energy-absorbing and energy-releasing characteristics of a young accommodative lens capsule. In another embodiment, the capsular shaping body is combined with an adaptive optic. The peripheral capsular shaping body carries at least one fluid-filled interior chamber that communicates with a space in a adaptive optic portion that has a deformable lens surface. The flexing of the peripheral shaping body in response to zonular tensioning and de-tensioning provides an inventive adaptive optics mechanism wherein fluid media flows between the respective chambers “adapts” the optic to increase and decrease the power thereof. In one embodiment, the capsular shaping body carries a posterior negative power adaptive optic that can be altered in power during accommodation to cooperate with an independent drop-in exchangeable intraocular lens.

A deformable intracapsular implant device for shaping an enucleated lens capsule sac for use in cataract procedures and refractive lensectomy procedures. In one embodiment, the intraocular implant devices rely on thin film shape memory alloys and combine with the post-phaco capsular sac to provide a biomimetic complex that can mimic the energy-absorbing and energy-releasing characteristics of a young accommodative lens capsule. In another embodiment, the capsular shaping body is combined with an adaptive optic. The peripheral capsular shaping body carries at least one fluid-filled interior chamber that communicates with a space in a adaptive optic portion that has a deformable lens surface. The flexing of the peripheral shaping body in response to zonular tensioning and de-tensioning provides an inventive adaptive optics mechanism wherein fluid media flows between the respective chambers “adapts” the optic to increase and decrease the power thereof. In one embodiment, the capsular shaping body carries a posterior negative power adaptive optic that can be altered in power during accommodation to cooperate with an independent drop-in exchangeable intraocular lens.

A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.

An intraocular lens is provided that having optical parameters that may be adjusted in-situ, and is particularly useful in cataract patients that require an adjustment in the optical power of the lens post-implantation. The lens body carries an array of interior fluid-filled cells in which fluid is controllably moved by micropumps upon application of energy from an external source to move a fluid media into the cells to thereby alter the lens surface shape.

A method of crystalline lens replacement for eyes comprises the steps of forming a small hole that penetrates through the lens capsule, removing a part of the crystalline lens substance through the hole, refilling the lens capsule by injecting a composition comprising a hydrophilic polymer directly into the lens capsule, and closing the hole. The method of crystalline lens replacement may be performed on animals or humans. Furthermore, the method of crystalline lens replacement may be performed on a patient suffering from cataract, where the opaque crystalline lens substance in the lens capsule is removed.

A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.

An intraocular lens (IOL) that provides for optical power adjustment following its implantation, for example, for use in treating cataract patients. The lens body has first and second surface portions that bound at least one interior chamber or space that extends from the central optic portion to the lens periphery. The interior chamber or space has a microporous body that is intermediate inner and outer portions of the space. In one embodiment, the microporous body is capable of cooperating with an external Rf or light source to expose a charge to a charge-carrying fluid within the interior chamber. By this system, fluid flows are induced to alter the optical parameters of the lens.

Devices and methods for use in laser-assisted surgery, particularly cataract surgery. Specifically, the use of an optical fiber with a proximal and distal end, wherein the distal end has a non-orthogonal angle with the diameter of the optical fiber, to create an off-axis steam bubble for cutting and removing tissue in an operative region. Where the optical fiber is bent, rotating the fiber creates a circular cutting path for the steam bubble, allowing access to tissues that may normally be blocked by obstructions and obstacles.

A two or three component lens system. The first component is a ring-like supporting component that is implanted in the capsular bag following cataract surgery. The first component is a non-optical component and does not correct for any refractive errors. The first component may contains features to help reduce or eliminate PCO. The second component is an optical component that may contain all of the corrective optical power of the lens system. The second component has a pair of tabs for locking the second component within the first component. The third component is optional and is similar to second component and contains some optical power to correct for any residual optical error not corrected by the second component. The second and third components may also be implanted so as to move relative to one another, thereby providing some accommodation.

An improved lens with Rugate filter specifically designed to be worn in prescription and non-prescription glasses, contact lenses, intraocular lenses and sunglasses, and to provide protection against macular degeneration by reducing harmful visible blue light transmission and ocular photochemical damage. The lens at least includes a single lens layer with a Rugate filter deposited thereon to selectively block visible blue light. Other layers may be added including a polarizing layer, dielectric layer and / or color tint in a lens sandwich configuration, to additionally give a high degree of UVA and UVB protection, color contrast, and glare reduction. The Rugate filter is a stop band which yields an exceptional light transmission profile under all light conditions, thereby maximizing protection as well as clarity of vision. In the multi-layer embodiment, all of the lens layers provide comprehensive protection for preventing macular degeneration, cataracts and other ocular injuries, yet maintain a balanced light transmission profile for visual acuity.

An improved multi-layer performance lens for protective eyewear such as sunglasses which includes a pass band Rugate filter. The lens design is a sandwich configuration including a polarizing layer between two ophthalmic lens layers in a sandwich configuration, and a Rugate filter applied to one side thereof to yield an exceptional light transmission profile under all light conditions, thereby maximizing protection as well as clarity of vision. In addition, an optional dielectric layer and / or hydrophobic overcoat may be applied. The foregoing layers are arranged to provide a balanced light transmission profile optimum for preventing macular degeneration, cataracts and other ocular injuries.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

A two or three component lens system. The first component is a ring-like supporting component that is implanted in the capsular bag following cataract surgery. The first component is a non-optical component and does not correct for any refractive errors. The first component may contain features to help reduce or eliminate PCO. The second component is an optical component that may contain all of the corrective optical power of the lens system. The second component has a pair of tabs for locking the second component within the first component. The first component includes a feature that allows the surgeon to change the position of the second component along the optical axis of the lens system. The third component is optional and is similar to second component and contains some optical power to correct for any residual optical error not corrected by the second component. The second and third components may also be implanted so as to move relative to one another, thereby providing some accommodation.

An intra ocular lens arrangement having positive and negative lens elements which move during the eye's accommodation response in order to improve the image on the retina of objects viewed by the eye over a wide range of distances. The positive and negative lens elements either can be linked mechanically to constrain their relative movements or not linked. The lenses are positioned by an operating surgeon following cataract extraction in either the eye's ciliary sulcus or lens capsule. Alternatively, one of the lenses may be inserted into an eye that already has a lens implanted therein to further improve a person's vision. An improved intra ocular lens has is an optic lens having at least two pairs of haptics that controls the movement of the optic lens along the optical axis of the eye in response to the movement of the ciliary muscle of the eye acting on the haptics during the accommodation response, one pair of haptics having one end hinged to the lower half of the optic lens and the second end connected to an upper portion of the ciliary muscle, and a second pair of haptics hinged to an upper half of the optic lens and to a lower potion of the ciliary muscle.